Fig. 6.
![Fig. 6. Subcellular fractionation of resting, FMLP-activated, and phagocytosing human PMNs. Distribution profiles of the PLD products, PA and PEt. PMNs were labeled with 1-O-[3H] octadecyl-sn-glycero-3 phosphocholine, activated and fractionated as described in Experimental Procedures. PA and PEt were detected as previously described.38](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/91/12/10.1182_blood.v91.12.4761/4/blod41224006y.jpeg?Expires=1735544462&Signature=oTih26bGOQCIxeA2BH4TCB4wbCU32zHh6VFKoSuzLap8SydnvoVmbzFN9iDxLWnp7PWe63XR9tM9Cuex50Xx2vWUtrr-ZLr6kADQbeC7zibjeebR1CsWJP0u~Zx5HpbVy2xF1MfNX7Q0WyF-i4jJ1fDp6dCrDEKyuN4Byu9Cun289fmFaTOEdwR2mBvMILAhpHqEol7fowO9zV7Ka4pSfUbys2RyMfHfKP4JI37k3jmke6b66ykXyovXAtuhWJftKSQFMdOhmgvQNB2R4dK~O608P4KmFDLUK6WNoG~SC90maoSQhrKQz4kvCFnqSjhQLoeAyMyhC-2kpeMddWlJ3w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Subcellular fractionation of resting, FMLP-activated, and phagocytosing human PMNs. Distribution profiles of the PLD products, PA and PEt. PMNs were labeled with 1-O-[3H] octadecyl-sn-glycero-3 phosphocholine, activated and fractionated as described in Experimental Procedures. PA and PEt were detected as previously described.38
